40% fail chemotherapy and then 40% of them who can afford Auto CAR-T will also fail this treatment. Azer-Cel is targeting an unmet market who have failed 5-6 treatments of chemotherapy and Auto CAR-T so they will have a faster path to commercialisation as this will be their last treatment option hence why the FDA granted Fast Track designation and why Azer-Cel's development will eventually surpass Allogene's cema-Cel.
If Azer-Cel is proven to work on those patients who have gone through 5-6 SoC treatments so are at the worst possibly physical and mental state, wouldn't it work even better for those who are in the optimal physical and mental state without enduring 5-6 previous treatments???
IMU Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)